WO2002002104A1 - Urushiol induced contact dermatitis treatment and method of use - Google Patents

Urushiol induced contact dermatitis treatment and method of use Download PDF

Info

Publication number
WO2002002104A1
WO2002002104A1 PCT/US2000/018462 US0018462W WO0202104A1 WO 2002002104 A1 WO2002002104 A1 WO 2002002104A1 US 0018462 W US0018462 W US 0018462W WO 0202104 A1 WO0202104 A1 WO 0202104A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
composition
urushiol
contact dermatitis
induced contact
Prior art date
Application number
PCT/US2000/018462
Other languages
French (fr)
Inventor
William M. Yarbrough
Original Assignee
The William M. Yarbrough Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The William M. Yarbrough Foundation filed Critical The William M. Yarbrough Foundation
Priority to AU2000259157A priority Critical patent/AU2000259157A1/en
Publication of WO2002002104A1 publication Critical patent/WO2002002104A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8105Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • A61K8/8111Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/925Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A treatment of urushiol induced contact dermatitis is provided for in a topical treatment. According to the invention, a method is provided for applying a composition of substances of the effected area, working the composition into the effected area, and removing the composition from the effected area. The composition comprises at least one ethoxylate in combination with Sodium Lauroyl Sarcominates (or 'SLS'). It is believed that this combination binds to the available urushiol receptors rendering it inactive. The affinity of the receptors for the ethoxylates also appears to causes a release of the urushiol from its epidermal bonds for bonding to the composition. An inert scrubbing agent, such as polyethylene beads, can also be included to assist in the release of the urushiol. Acetylated lanolin, sodium lauroyl sarcominate, EDTA, a foam stabilizer, and water can also be added to the composition without the effecting performance.

Description

URUSHIOL INDUCED CONTACT DERMATITIS TREATMENT AND METHOD OF USE
I. FIELD OF THE INVENTION The present invention relates to treatments for allergic dermatitis and more particularly, to a treatment for Toxicodendron dermatitis, which results from contact with the Rhus oleoresin urushiol. II. BACKGROUND OF THE INVENTION AND PRIOR ART
Urushiol is the toxin responsible for the allergic dermatitis caused by contact with the sap of commonly encountered noxious plants such as poison ivy, poison oak, and poison sumac, and related plants found throughout the world. Urushiol or related chemicals are also found in the Anacardiaceae group, which includes, among others, the lacquer tree of Asia, mango tree, cashew shell oil and in certain nut shells, such as the walnut. The American Academy of Dermatology estimates that there are up to 50 million cases of urushiol induced contact dermatitis annually in the United States alone. No one is sure of the number of world wide annual exposures but some experts estimate that the number could be double that of the United States. Accordingly, urushiol induced contact dermatitis is a world wide problem. Chemically, urushiols are mixtures of catechols with long, hydrophobic, carbon(alkyl) side chains at the three position of the catechol ring. For example, poison ivy contains predominantly 3-w-pentadececylcatechols (C-15) and poison oak contains predominantly 3-n- heptaecylcatechols (C-17). When located inside an unruptured plant leaf, Urushiol is a light, colorless oil. When exposed to oxygen, urushiol easily oxidizes arid, after polymerizing, turns a blackish color. The reaction is the result of exposure to the oleoresin containing the urushiol. The reaction is an allergic eczematous contact dermatitis characterized by redness, swelling, papules, vesicles, bullae, and streaking. Treatment has historically consisted of attempting to remove the oil as quickly after exposure as possible: applying rubbing alcohol, washing affected areas with water, and showering with soap and water. Unfortunately, if the above procedure is not commence within minutes of exposure the regimen will not remove the toxin but may limit its spread. Attempts have been made to find both prophylactic treatments as well as post- exposure treatments. To date, no vaccine has been developed and the prior art treatments are not without shortcomings. One treatment example is seen in U.S. Patent number 5,686,074 to Stewart which teaches and claims a treatment for poison ivy which includes a composition including linseed oil, an astringent, a starch, an essential oil and a citrus oil. One shortcoming of this patent is that linseed oil can cause irritation itself. A second shortcoming of this patent is that it requires that the composition be applied to the affected areas up to twice a day until the rash is gone. The composition provides what appears to be only very temporary palliative relief of poison ivy symptoms and does not appear to alter the course of the malady. Other proposed treatments are seen in U. S. Patent numbers 5,620,527, 5,011 ,689 4,499,086, 4,259,318, 4,002,737, 3,862,331, 3,875,301, and 3,922,342. Yet other prior art attempts have focused on prophylactics for preventing the dermatitis. One example is seen is U.S. Patent number 4,663,151 to Waali which discloses and claims a prophylactic treatment based upon Aluminum Chlorhydrate. Of course, the most significant shortcoming associated with prophylactic treatments is that they are only effective if applied before exposure to the urushiol; an occurrence that rarely takes place. A significant advance in the treatment of poison ivy is seen in an unpatented product sold under the mark Tech-Nu ® and manufactured by Tec Laboratories, Inc. of Albany, Oregon. However, this product is not without shortcomings. This product was originally developed as a treatment for radiation exposure. It was discovered, however, that the product also provided some relief for poison ivy exposure. The main active ingredient in the Tech-nu® product is Octylphenoxy-polyethoxyethanol. The four octyl groups of this chemical are to large too surround the non polar moieties in the urushiol. Therefore, it only partially matches the polarity of urushiol. Thus, the action of this product renders the urushiol only partially inactive. Since the urushiol remains partially active and continues to cause irritation, only temporary relief is provided and multiple applications are necessary. Also, the chemical makeup of the product requires that it be applied no later than eight hours after exposure to urushiol. There is need, therefore, for a safe, effective treatment for dermatitis caused by exposure to the toxin urushiol. The treatment should provide complete relief from the signs and symptoms associated with the dermatitis in limited treatments and be effective at any point during the dermatitis cycle. II. OBJECTS OF THE INVENTION It is an object of the present invention to provide a treatment for urushiol induced allergic dermatitis, the treatment providing almost immediate and permanent relief in usually one treatment. It is a further object of the present invention to provide such a treatment in a method that utilizes a composition that chemically attaches to available urushiol receptors to block its allergic reaction properties and to release the urushiol so that it can be removed from the skin. It is yet another object of the present invention to provide a treatment for urushiol induced contact dermatitis that includes a first nonyl phenyl ethoxylate, a second nonyl phenyl ethoxylate, acetylated lanolin alcohol, sodium lauroyl sarcominate, EDTA, a foam stabilizer, water, and inert polyethylene granules. It is a yet further object of the present invention to provide a treatment which is safe to use. It is yet another object of the present invention to provide a treatment for urushiol induced allergic dermatitis which is topical, can be purchased over the counter and is economical. IV. SUMMARY OF THE INVENTION The above objects of the invention are provided for in a topical treatment for urushiol induced contact dermatitis. According to the invention, a method is provided for applying a composition of substances to the effected area, working the composition into the effected area, and removing the composition from the effected area. The composition comprises at least one ethoxylate in combination with Sodium Lauroyl Sarconinate (or "SLS"). It is believed that this combination binds to the available urushiol receptors-i rendering it inactive. The affinity of the receptors for the ethoxylates also appears to cause a release of the urushiol from its epidermal bonds for bonding to the composition. An inert scrubbing agent, such as polyethylene beads, can also be included to assist in the release of the urushiol. Acetylated lanolin alcohol, 'sodium lauroyl sarcominate, EDTA, a foam stabilizer, and water can also be added to the composition without effecting performance. V. DETAILED DESCRIPTION OF THE INVENTION As noted above, urushiol is the toxin responsible for the contact dermatitis caused by poison ivy, poison oak, and other urushiol containing plants. When housed inside an unruptured plant leaf, urushiol is a light, colorless oil. The leaves are easily-damaged by the slightest contact or even breeze. Therefore, it is rare to find a plant that does not have at least some ruptured leaves. When exposed to oxygen, urushiol easily oxidizes and, after polymerizing, turns a blackish color. The reaction experienced by most people is the result of exposure to the oleoresin containing the urushiol. The reaction is an allergic eczematoμs contact dermatitis characterized by redness, swelling, papules, vesicles, bullae, and streaking. Urushiol is the name given to a family catechols having long, hydrophobic, carbon(alkyl) side chains at the three position of the catechol ring. The chemical structure of the urushiol found in the poison ivy plant is:
OH OH (CHJ7CH CH(CH2)5CH2 t is seen that the urushiol of the poison ivy plant contains predominantly 3-n- pentadececylcatechols (C-l 5). Poison oak is known to contain predominantly 3-n- heptaecylcatechols (C-l 7). Other urushiol containing plants contain catechols that have side chains of varying lengths. It has been discovered that a hand scrub product manufactured and sold by the Redman Scientific, Company of Dallas, Texas can alleviate the signs and symptoms of urushiol induced contact dermatitis. The product has been sold for approximately twenty years, and is known to be a safe, gentle hypoallergenic product. The product has been sold as an industrial hand cleaner and has never heretofore been known to be effective against urushiol toxicity. It has only been promoted as a hand cleaner. Chemical analysis and research by the inventors has revealed that two of the component parts of the Redman product are central to its effectiveness as a treatment for urushiol induced contact dermatitis: an ethoxylate and Sodium Lauroyl Sarconinate. The ethoxylate is a nonylphenel ehtoxylate, Unlike the ethoxylate of the Tech-Nu ® product, the present invention's ethoxylate has the large octyl groups removed. In this way, the ethoxylate can "wrap" around the non-polar molecules of the urushiol. Further, the long chain moiety of the present invention's ethoxylate is only four carbons long, as opposed to ten. This feature also assists the ethoxylate in bonding to the urushiol more effectively. However, the ethoxylate itself is not capable of forming a complete micelle around the urushiol. The inventors have discovered that the addition of Sodium Lauroyl Sarcosinide, the micelle is completed and the urushiol can be cleansed away from the skin. SLS also has a long carbon chain that can surround the non-polar portions of the urushiol. In addition, SLS contains a highly polar end that aids in surrounding the polar ends of urushiol and also in the invention's reactivity with water. Thus, the combination of the ethoxylate and SLS create a large molecule that contains flexible non-polar groups and soluble polar groups. This permits the inventive composition to quickly and effectively surround the urushiol and then be rinsed away with water, a highly polar substance. The inventors have also discovered that the addition of an inert scrubbing agent improves the action of the inventive composition. The scrubbing agent assists by causing the urushiol to detach from the skin and place it in position for bonding with the active chemical components of the inventive composition. Any inert agent will suffice but the inventors believe that poly ethylene beads work best. The beads should be large enough to be effective but not so large as to cause abrasions. The inventors suggest beads in the range of 5 to 50 microns with an average size being approximately 25 microns or 50 mesh. To make the inventive composition, an exact ratio of ethoxylate to SLS is not critical. The only requirement is that the ethoxylate is completely reacted with the SLS, creating a polymer. This will vary with the ethoxylate used, but the inventors have determined that a ratio of ethoxylate-to- SLS of 1.5:2 is preferred. The amount by weight of polyethylene beads can vary according to the grittiness desired. The inventors have found that a formula of ethoxylate: SLS .-polyethylene of 40:20:40 is preferred but that formulas of other concentrations are useful. Thus, for production purposes, formulas having SLS ranging from 10 to 20 % by weight, ethoxylate ranging from 20 to 40 % by weight, and polyethylene beads from 20 to 50% by weight are reasonable. But again, the formula is not restricted to these ranges, which ranges are presented for example purposes only. Also, a cutting agent that does not chemically react with the composition may be added. The cutting agent makes the overall composition flow more easily, thereby enabling more packaging options such as tubes. The cutting agent must be added only in sufficient amount that it promotes flow but does not effect the action of the cornposition. In use, the composition is applied to an effected area and worked over the area by a scrubbing motion. After sufficient time has elapsed to ensure that the effected area has been adequately exposed to the composition, the composition and bound urushiol are washed away. Experiments have demonstrated that a majority of people need only one treatment to be relieved of itching; however, severe cases may require two treatments approximately eight hours apart. The inventive composition works at varying rates of effectiveness at any time during the rash cycle.

Claims

WE CLAIM: 1. A treatment for urushiol induced contact dermatitis comprising sodium lauroyl _ sarcominate and a nonyl phenyl ethoxylate in combination.
2. The treatment for urushiol induced contact dermatitis of Claim 1 further including a second nonyl phenyl ethoxylate.
3. The treatment for urushiol induced contact dermatitis of Claim 1 further including acetylated lanolin alcohol.
4. The treatment for urushiol induced contact dermatitis of Claim 1 further including polyethylene granules.
5. The treatment for urushiol induced contact dermatitis of Claim 1 further including water.
6. The treatment for urushiol induced contact dermatitis of Claim 1 further including ethylenediaminetetraacetic acid.
7. The treatment for urushiol induced contact dermatitis of Claim 1 further including a foam stabilizing agent.
8. The treatment for urushiol induced contact dermatitis of Claim 1 further including a cutting agent.
9. The cutting agent of Claim 8 being selected from the group of aqueous based solutions and oil based solutions.
10. A treatment for urushiol induced contact dermatitis comprising a nonyl phenyl ethoxylate, sodium lauroryl sarcominate, and scrubbing means.
11. The treatment of Claim 10 wherein the scrubbing meanήs polyethylene beads.
12. The treatment for urushiol induced contact dermatitis of Claim 10 fiirther including a cutting agent.
13. A treatment for urushiol induced contact dermatitis comprising: a first nonyl phenyl ethoxylate, a second nonyl phenyl ethoxylate, acetylated lanolin alcohol, sodium lauroyl sarcominate, EDTA, a foam stabilizer, water, and inert polyethylene granules.
14. A treatment for urushiol induced contact dermatitis comprising a nonyl phenyl ethoxylate, sodium lauroyl sarcominate, and EDTA.
15. A method for treating contact dermatitis comprising the steps of: preparing a composition comprising a nonyl phenyl ethoxylate and sodium lauroyl sarcominate; applying the composition to an infected area; permitting the composition to remain on the infected area a sufficient amount of time to enable the composition of matter to cause an effect; and, removing the composition from the effected area,
16. The method of Claim 15 wherein preparing the composition further includes adding second nonyl phenyl ethoxylate.
17. The method of Claim 15 wherein preparing the composition further includes adding acetylated lanolin alcohol.
18. The method of Claim 15 wherein preparing the composition further includes adding acetylated polyethylene granules.
19. The method of Claim 15 wherein preparing the composition further includes adding water.
20. The method of Claim 11 wherein preparing the composition further includes EDTA.
21. The method of Claim 11 wherein preparing the composition further includes a foam stabilizer.
22. The method of Claim 15 further including the step of adding a tWnning agent to the composition.
PCT/US2000/018462 1999-07-03 2000-07-06 Urushiol induced contact dermatitis treatment and method of use WO2002002104A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2000259157A AU2000259157A1 (en) 1999-07-03 2000-07-06 Urushiol induced contact dermatitis treatment and method of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34771400A 2000-07-03 2000-07-03
US09/347,714 2000-07-03

Publications (1)

Publication Number Publication Date
WO2002002104A1 true WO2002002104A1 (en) 2002-01-10

Family

ID=23364920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/018462 WO2002002104A1 (en) 1999-07-03 2000-07-06 Urushiol induced contact dermatitis treatment and method of use

Country Status (1)

Country Link
WO (1) WO2002002104A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656017A1 (en) * 2003-08-12 2006-05-17 The William M. Yarbrough Foundation Composition for treatment of biting and penetrating organisms and parasites, and urticaria and method of use
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620527A (en) * 1986-07-16 1997-04-15 The Sterilex Corporation Cleansing and disinfecting method
US5833999A (en) * 1994-10-20 1998-11-10 The Proctor & Gamble Company Personal treatment compositions and /or cosmetic compositions containing enduring perfume
US5888520A (en) * 1996-04-30 1999-03-30 Hydromer, Inc. Composition, barrier film, and method for preventing contact dermatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620527A (en) * 1986-07-16 1997-04-15 The Sterilex Corporation Cleansing and disinfecting method
US5833999A (en) * 1994-10-20 1998-11-10 The Proctor & Gamble Company Personal treatment compositions and /or cosmetic compositions containing enduring perfume
US5888520A (en) * 1996-04-30 1999-03-30 Hydromer, Inc. Composition, barrier film, and method for preventing contact dermatitis

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656017A1 (en) * 2003-08-12 2006-05-17 The William M. Yarbrough Foundation Composition for treatment of biting and penetrating organisms and parasites, and urticaria and method of use
EP1656017A4 (en) * 2003-08-12 2008-11-05 William M Yarbrough Foundation Composition for treatment of biting and penetrating organisms and parasites, and urticaria and method of use
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11857666B2 (en) 2020-02-14 2024-01-02 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
US11951200B2 (en) 2020-02-17 2024-04-09 The William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions

Similar Documents

Publication Publication Date Title
US6423746B1 (en) Urushiol induced contact dermatitis and method of use
US10561626B2 (en) Method for treating urushiol induced contact dermatitis
CA2535550A1 (en) Treatment for acne vulgaris and method of use
US5756560A (en) Method and composition for promoting improved adhesion to substrates
WO2012018888A2 (en) An antiseptic liquid formulation, a method for its use, and a method for preparing the formulation
EP1762227B1 (en) Compositions, uses and kits for treating allergic dermatitis of skin
WO2003070206A1 (en) Treating agent for protecting animal fiber
JP2007505093A5 (en)
WO2002002104A1 (en) Urushiol induced contact dermatitis treatment and method of use
FR2782923A1 (en) Transforming cosmetic composition into film, for use as face mask, involves mixing composition with at least one alginate salt, and mixing resulting mixture with calcium salt
JP2010095472A (en) Hair care cosmetic
WO2004052358A1 (en) Urushiol induced contact dermatitis treatment and method of use
FR2681782A1 (en) COMPOSITION FOR THE TREATMENT OF NAILS CONTAINING A SULFUR AMINOACID.
US11951200B2 (en) Sodium lauroyl sarcosinate containing detergent compositions
US20060177400A1 (en) Topical formulation for the treatment of urushiol induced contact dermatitis and method for treating the same
EP0621034B1 (en) Composition containing aluminium complexes for the treatment of chemical or heat burns
JP2994565B2 (en) Dye remover
JP2003128527A (en) Composition for removing dyed color of hair
US11154486B2 (en) Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
WO1993003706A1 (en) Compositions and methods for altering the color of hair
US5021455A (en) Solution for neutralizing caustic effects of alkaline cementitious materials on human skin
SU1683752A1 (en) Cream for skin hands protection against anthracyclinic antibiotics
RU2308304C1 (en) Agent for dry hand skin cleaning
WO2012126198A1 (en) Acid-base neutralizing solution for chemical burning protection
JPH0769850A (en) Composition for hair treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP KP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP